Paragon Biosciences was awarded the Overall BioTech Company of the Year in the 2026 BioTech Breakthrough Awards for its innovative approach to developing therapies for overlooked medical conditions. The company builds and funds biology-based firms, advancing treatments such as Emalex Biosciences' therapy for Tourette syndrome, now under FDA Priority Review after acquisition by Teva Pharmaceuticals. Paragon's portfolio includes companies focused on rare neurological diseases, AI-designed protein therapeutics, and regenerative medicine, highlighting its role in accelerating biotech innovation globally.
Paragon Biosciences' recent accolade as Overall BioTech Company of the Year comes with this market context from Pluang. Of 150 priced Health-sector US stocks tradable on Pluang, 87 rose and 56 fell today. Notable movers include Inovio Pharmaceuticals Inc at USD 1.56 with a -3.70% change, Edwards Lifesciences Corporation at USD 103.00 with a +3.65% change, and Zoetis Inc at USD 92.33 with a +3.54% change. This data is as of Nov 05, 2026 19:42 WIB.
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
Perimeter Group Inc. announced a net income of $304.5 million for Q3 2026, reversing a prior year loss of $90.7 million, with net sales up 24% to $389.9 million. Growth was driven by a 14% increase in Fire Safety sales and an 84% surge in Specialty P...
